Tweet
Oncotarget. 2017 Jul 13;8(33):55176-55186. doi: 10.18632/oncotarget.19220. eCollection 2017 Aug 15.
Efficacy and safety of Re-Du-Ning injection in the treatment of seasonal influenza: results from a randomized, double-blinded, multicenter, oseltamivir-controlled trial.
Liu Y1,2, Mu W2, Xiao W3, Wei BL2, Wang L4, Liu XQ5, Xiong XD6, Huang XM7, Zhang YQ8, Chen HM9, Yan FJ10, Tan YP11, Huang YH2.
Author information
Abstract
OBJECTIVE:
To assess the efficacy and safety of RDNI in the treatment of seasonal influenza.
RESULTS:
1575 participants were screened and 229 completed the study and had a RT-PCR laboratory confirmation of influenza virus infection. Fever alleviation time was 2 and 6 hours, and fever clearance time was 27 and 47 in RDNI and oseltamivir, with significant difference between two groups. Total scores of influenza symptoms descended more in RDNI than oseltamivir on day 2 and day 3. Single symptom such as fever, aversion to cold, sore throat and nasal obstruction score descended more in RDNI than oseltamivir on different days. 20 subjects used aspirin during the trial, and there was no significant difference between two groups.
MATERIALS AND METHODS:
We conducted a randomized, double-blind, double-dummy, oseltamivir controlled clinical trial. Patients with a positive influenza rapid test diagnosis were enrolled and randomized to receive RDNI or oseltamivir. Primary outcome was the median fever alleviation and clearance time. Secondary outcomes were total 8 influenza symptom scores, the single influenza symptom score, and the frequency of aspirin usage.
CONCLUSIONS:
The effect of RDNI was not worse than oseltamivir on the alleviation of influenza symptoms. RDNI was well tolerated, with no serious adverse events noted during the study period.
KEYWORDS:
Re-Du-Ning injection; clinical trial; oseltamivir; seasonal influenza
PMID: 28903411 PMCID: PMC5589650 DOI: 10.18632/oncotarget.19220
Efficacy and safety of Re-Du-Ning injection in the treatment of seasonal influenza: results from a randomized, double-blinded, multicenter, oseltamivir-controlled trial.
Liu Y1,2, Mu W2, Xiao W3, Wei BL2, Wang L4, Liu XQ5, Xiong XD6, Huang XM7, Zhang YQ8, Chen HM9, Yan FJ10, Tan YP11, Huang YH2.
Author information
Abstract
OBJECTIVE:
To assess the efficacy and safety of RDNI in the treatment of seasonal influenza.
RESULTS:
1575 participants were screened and 229 completed the study and had a RT-PCR laboratory confirmation of influenza virus infection. Fever alleviation time was 2 and 6 hours, and fever clearance time was 27 and 47 in RDNI and oseltamivir, with significant difference between two groups. Total scores of influenza symptoms descended more in RDNI than oseltamivir on day 2 and day 3. Single symptom such as fever, aversion to cold, sore throat and nasal obstruction score descended more in RDNI than oseltamivir on different days. 20 subjects used aspirin during the trial, and there was no significant difference between two groups.
MATERIALS AND METHODS:
We conducted a randomized, double-blind, double-dummy, oseltamivir controlled clinical trial. Patients with a positive influenza rapid test diagnosis were enrolled and randomized to receive RDNI or oseltamivir. Primary outcome was the median fever alleviation and clearance time. Secondary outcomes were total 8 influenza symptom scores, the single influenza symptom score, and the frequency of aspirin usage.
CONCLUSIONS:
The effect of RDNI was not worse than oseltamivir on the alleviation of influenza symptoms. RDNI was well tolerated, with no serious adverse events noted during the study period.
KEYWORDS:
Re-Du-Ning injection; clinical trial; oseltamivir; seasonal influenza
PMID: 28903411 PMCID: PMC5589650 DOI: 10.18632/oncotarget.19220